POLICLINICO SAN DONATO SPA

Their core work

IRCCS Policlinico San Donato is a major Italian private research hospital (IRCCS-designated) located near Milan, specializing in clinical research across cardiovascular medicine, oncology, and immune-mediated diseases. In H2020, they contributed clinical data, patient cohorts, and biomarker expertise to large European consortia focused on disease stratification and diagnostic innovation. Their work spans from genetics and multiomics profiling of multiple sclerosis to AI-driven cancer imaging and COVID-19 prognostic biomarkers, reflecting a hospital that actively bridges bedside patient care with translational research.

What they specialise in

How they've shifted over time

Their earliest H2020 work (MultipleMS, starting 2017) focused on fundamental disease mechanisms — genetics, epigenetics, and immune profiling in multiple sclerosis. By 2020, their focus shifted decisively toward applied diagnostics: AI-powered cancer imaging tools (CHAIMELEON) and rapid prognostic testing for COVID-19 (COVIRNA). This trajectory shows a clear move from understanding disease biology toward deploying translational diagnostic technologies, with AI and imaging becoming central to their research identity.

They are moving toward AI-integrated clinical diagnostics, making them a strong fit for future projects combining medical imaging, machine learning, and regulatory-compliant clinical validation.

How they like to work

Policlinico San Donato participates exclusively as a consortium partner, never as coordinator — consistent with a clinical research hospital that provides patient data, imaging infrastructure, and clinical validation rather than project management. With 53 unique partners across 20 countries from just 3 projects, they operate in large, multi-national consortia typical of ambitious health research. This makes them an accessible partner: experienced in large-consortium dynamics, comfortable contributing specialized clinical assets without needing to lead.

Despite only three projects, they have built a broad network of 53 partners across 20 countries, indicating participation in large pan-European health consortia. Their reach spans most of the EU, with no narrow geographic concentration.

What sets them apart

As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), Policlinico San Donato holds Italy's highest designation for clinical research hospitals, meaning they combine active patient care with structured research programs. This gives them something most research-only partners cannot offer: direct access to real patient cohorts, clinical imaging data, and the regulatory environment needed for in-vivo diagnostic validation. For consortium builders needing a clinical site in Italy with experience across oncology, cardiovascular, and immune diseases, they are a proven and versatile choice.

Highlights from their portfolio

• CHAIMELEON
  Largest project by funding (EUR 386K), combining AI, radiomics, and regulatory compliance for cancer imaging across four major cancer types — their most ambitious and applied contribution.
• COVIRNA
  Rapid-response COVID-19 project applying long non-coding RNA biomarkers and AI prediction models to patient stratification — demonstrates agility in pivoting to urgent health challenges.